Ticagrelor (Brilinta; AstraZeneca) doesn’t lessen risks of MI or death and may increase bleeding relative to clopidogrel, according to the results of a study in a real-world ACS population. Across ...

A recent opinion paper concluded that timely revascularization and dual antiplatelet therapy (DAPT) are crucial in the ...

Ticagrelor may not have an advantage over clopidogrel as part of a dual antiplatelet therapy (DAPT) regimen when it comes to treating ACS patients who have undergone PCI in everyday practice, a large ...

ORLANDO, Fla.—AstraZeneca may have just found a new niche for blood thinner Brilinta. Sunday at the American College of Cardiology's 67th Annual Scientific Session, the British pharma giant presented ...

HealthDay News — Ticagrelor is not superior to clopidogrel for reduction of cardiovascular events in patients with peripheral artery disease, according to a study published online November 13 in the ...

New data from a late-stage, head-to-head trial demonstrates that a group of the sickest heart attack patients taking AstraZeneca's experimental blood clot drug Brilinta experienced fewer serious ...

This morning, AstraZeneca (AZN) announced positive top-line results of its phase III 18,600-patient PLATO trial, comparing AZN's Brilinta (ticagrelor) with Plavix (clopidogrel) in the reduction of ...

ORLANDO, Fla., Nov 15 (Reuters) - Heart attack patients in need of emergency procedures were less likely to suffer further serious cardiovascular events, including death, when given AstraZeneca's ...

Top-line results of the EUCLID trial did not demonstrate a benefit of ticagrelor over clopidogrel for prevention of atherothrombotic events in patients with symptomatic peripheral artery disease, ...

Among patients with ACS who underwent PCI and received an outpatient prescription for ticagrelor or clopidogrel, ticagrelor was not associated with a significant reduction in risk for MACE, and those ...